IDYA

MKT CAP:$3B

IDEAYA Biosciences, Inc.

Market Cap

$3B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$32.09-$1.76 (-5.19%)

Apr 22, 2026

Company Details

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead ...

CEO

Yujiro S. Hata

IPO Date

May 23, 2019

Website

www.ideayabio.com

Key Metrics TTM

Revenue

$219M

+3024.4% YoY

Net Income

-$114M

EPS (Diluted)

-$1.31

Free Cash Flow

-$73M

Revenue / Share

$2.47

Gross Margin

97.9%

Operating Margin

-72.8%

Net Margin

-52.0%

FCF Margin

-33.6%

P/S

12.3x

P/E

—

Earnings Reports

Q1 2026

May 5, 2026

PENDING

FY 2025

Feb 17, 2026

$219M+3024.4%EPS -$1.28

Q4 2025

Feb 17, 2026

$11M+55.4%EPS -$0.94

Q3 2025

Nov 4, 2025

$208MEPS $1.33

Q2 2025

Aug 5, 2025

$0EPS -$0.88

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$11M	$11M	-$14M
Q2 22	$6M	$5M	-$22M
Q3 22	$30M	$29M	$660.0K
Q4 22	$4M	$3M	-$26M
Q1 23	$8M	$7M	-$26M
Q2 23	$4M	$3M	-$33M
Q3 23	$8M	$7M	-$34M
Q4 23	$4M	$3M	-$42M
Q1 24	$0	-$1M	-$51M
Q2 24	$0	-$1M	-$65M
Q3 24	$0	-$1M	-$67M
Q4 24	$7M	$6M	-$144M
Q1 25	$0	-$1M	-$84M
Q2 25	$0	-$1M	-$89M
Q3 25	$208M	$207M	$108M
Q4 25	$11M	$10M	-$95M

Valuation

Quarter	P/S	P/E
Q1 22	83.9x	—
Q2 22	92.2x	—
Q3 22	53.9x	—
Q4 22	52.8x	—
Q1 23	56.7x	—
Q2 23	59.6x	—
Q3 23	114.5x	—
Q4 23	115.0x	—
Q1 24	173.4x	—
Q2 24	224.8x	—
Q3 24	685.3x	—
Q4 24	384.1x	—
Q1 25	384.1x	—
Q2 25	384.1x	—
Q3 25	12.5x	—
Q4 25	12.3x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$20M	-$20M
Q2 22	-$20M	-$22M
Q3 22	-$24M	-$25M
Q4 22	-$23M	-$23M
Q1 23	-$28M	-$28M
Q2 23	-$33M	-$34M
Q3 23	-$30M	-$31M
Q4 23	-$24M	-$25M
Q1 24	-$44M	-$45M
Q2 24	-$33M	-$34M
Q3 24	-$49M	-$50M
Q4 24	-$122M	-$123M
Q1 25	-$60M	-$62M
Q2 25	-$62M	-$63M
Q3 25	$142M	$142M
Q4 25	-$90M	-$91M

Capital Expenditures

Quarter	CapEx
Q1 22	$401.0K
Q2 22	$2M
Q3 22	$1M
Q4 22	$0
Q1 23	$43.0K
Q2 23	$884.0K
Q3 23	$603.0K
Q4 23	$838.0K
Q1 24	$1M
Q2 24	$973.0K
Q3 24	$457.0K
Q4 24	$1M
Q1 25	$1M
Q2 25	$663.0K
Q3 25	$42.0K
Q4 25	$333.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	+56.7%	+56.1%
Q2 22	-33.2%	+43.1%
Q3 22	+230.9%	+40.4%
Q4 22	+35.7%	+42.8%
Q1 23	-30.6%	+33.5%
Q2 23	-39.4%	+27.9%
Q3 23	-72.9%	+43.1%
Q4 23	-2.5%	+50.5%
Q1 24	-100.0%	+49.4%
Q2 24	-100.0%	+79.1%
Q3 24	-100.0%	+60.9%
Q4 24	+78.4%	+229.7%
Q1 25	—	+65.4%
Q2 25	—	+36.8%
Q3 25	—	+48.6%
Q4 25	+55.4%	-30.2%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$3M	22.9%
Q2 22	$3M	52.0%
Q3 22	$3M	10.1%
Q4 22	$3M	74.0%
Q1 23	$4M	46.4%
Q2 23	$5M	133.5%
Q3 23	$5M	65.9%
Q4 23	$5M	122.3%
Q1 24	$6M	—
Q2 24	$10M	—
Q3 24	$9M	—
Q4 24	$9M	135.5%
Q1 25	$10M	—
Q2 25	$12M	—
Q3 25	$12M	5.9%
Q4 25	$0	0.0%

OpEx Breakdown

Quarter	R&D	SG&A
Q1 22	$20M	$5M
Q2 22	$23M	$4M
Q3 22	$22M	$6M
Q4 22	$25M	$5M
Q1 23	$28M	$5M
Q2 23	$29M	$6M
Q3 23	$34M	$7M
Q4 23	$39M	$6M
Q1 24	$43M	$7M
Q2 24	$55M	$9M
Q3 24	$57M	$9M
Q4 24	$140M	$10M
Q1 25	$71M	$12M
Q2 25	$74M	$13M
Q3 25	$83M	$15M
Q4 25	$87M	$18M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$55M	$197M	$253M
Q2 22	$49M	$220M	$269M
Q3 22	$102M	$284M	$386M
Q4 22	$69M	$296M	$365M
Q1 23	$67M	$272M	$339M
Q2 23	$103M	$391M	$494M
Q3 23	$152M	$317M	$469M
Q4 23	$157M	$368M	$525M
Q1 24	$108M	$590M	$699M
Q2 24	$183M	$519M	$702M
Q3 24	$400M	$520M	$920M
Q4 24	$84M	$592M	$676M
Q1 25	$130M	$563M	$693M
Q2 25	$115M	$555M	$670M
Q3 25	$299M	$488M	$787M
Q4 25	$113M	$527M	$639M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	39M	+0.2%	+21.5%
Q2 22	39M	+0.2%	+17.7%
Q3 22	41M	+6.3%	+8.8%
Q4 22	48M	+17.1%	+25.0%
Q1 23	48M	+0.5%	+25.3%
Q2 23	56M	+16.3%	+45.5%
Q3 23	60M	+6.7%	+46.0%
Q4 23	65M	+8.7%	+35.6%
Q1 24	75M	+15.1%	+55.3%
Q2 24	78M	+3.8%	+38.6%
Q3 24	86M	+10.6%	+43.6%
Q4 24	87M	+1.3%	+33.9%
Q1 25	88M	+1.2%	+17.6%
Q2 25	88M	+0.1%	+13.5%
Q3 25	90M	+1.4%	+4.1%
Q4 25	89M	-1.2%	+1.4%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$140.2K	81
Q2 22	$72.2K	81
Q3 22	$366.7K	81
Q4 22	$39.0K	103
Q1 23	$76.5K	103
Q2 23	$34.4K	103
Q3 23	$78.0K	103
Q4 23	$31.6K	124
Q1 24	$0	124
Q2 24	$0	124
Q3 24	$0	124
Q4 24	$53.4K	131
Q1 25	$0	131
Q2 25	$0	131
Q3 25	$2M	131
Q4 25	$54	200K

Revenue / Employee